2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Lisberg discusses the excitement with datopotamab deruxtecan in non–small cell lung cancer and previews anticipated data from the NSCLC cohort of the TROPION-PanTumor01 trial at the International Association for the Study of Lung Cancer 2021 World Conference on Lung Cancer.
Welcome to OncLive On Air®! I’m your host today, Jessica Hergert.
OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, we had the pleasure of speaking with Aaron Lisberg, MD, an assistant professor of medicine and a hematologist and medical oncologist at UCLA Health, to discuss the data that has been generated with datopotamab deruxtecan (DS-1062-a) in non–small cell lung cancer (NSCLC).
Datopotamab deruxtecan is a differentiated TROP2-directed antibody-drug conjugate under study in the phase 1 TROPION-PanTumor01 trial (NCT03401385) in patients with advanced solid tumors.
The agent demonstrated encouraging antitumor activity and a manageable safety profile in patients with advanced or metastatic NSCLC, according to updated results of the trial that were presented during the 2021 ASCO Annual Meeting.
In our exclusive interview, Lisberg discussed the excitement with datopotamab deruxtecan in NSCLC and previewed anticipated data from the NSCLC cohort of the TROPION-PanTumor01 trial at the IASLC 2021 WCLC.
Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field. For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.
OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.
If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!
Thanks again for listening to OncLive On Air®.
*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.